Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
19M
-
Number of holders
-
139
-
Total 13F shares, excl. options
-
14.4M
-
Shares change
-
+6.75M
-
Total reported value, excl. options
-
$820M
-
Value change
-
+$416M
-
Put/Call ratio
-
1.72
-
Number of buys
-
103
-
Number of sells
-
-44
-
Price
-
$56.90
Significant Holders of NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR) as of Q3 2025
178 filings reported holding NKTR - NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value as of Q3 2025.
NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR) has 139 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.4M shares
of 19M outstanding shares and own 75.71% of the company stock.
Largest 10 shareholders include BVF INC/IL (1.28M shares), VANGUARD GROUP INC (949K shares), MORGAN STANLEY (929K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (925K shares), FARALLON CAPITAL MANAGEMENT LLC (791K shares), BlackRock, Inc. (609K shares), MILLENNIUM MANAGEMENT LLC (546K shares), TWO SIGMA INVESTMENTS, LP (434K shares), Nantahala Capital Management, LLC (419K shares), and CITADEL ADVISORS LLC (361K shares).
This table shows the top 139 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.